Top Page
Hansa Biopharma AB
(HNSA)
Hansa Biopharma AB (HNSA) vs. iShares MSCI Sweden ETF (EWD)
Hansa Biopharma AB Business Overview & Revenue Model
Hansa Biopharma AB Earnings Call Summary
Hansa Biopharma AB Financial Statement Overview
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 222.26M | 171.32M | 134.09M | 154.53M | 33.88M |
| Gross Profit | 138.71M | 87.76M | 70.95M | 116.05M | 18.45M |
| EBITDA | -409.35M | -642.07M | -714.55M | -554.26M | -538.83M |
| Net Income | -529.25M | -807.24M | -831.72M | -611.13M | -548.28M |
Balance Sheet | |||||
| Total Assets | 1.17B | 800.64M | 1.02B | 1.69B | 1.01B |
| Cash, Cash Equivalents and Short-Term Investments | 701.08M | 405.28M | 732.06M | 1.50B | 888.96M |
| Total Debt | 933.82M | 1.08B | 866.77M | 791.09M | 35.38M |
| Total Liabilities | 1.25B | 1.39B | 1.19B | 1.08B | 255.24M |
| Stockholders Equity | -84.13M | -589.83M | -167.88M | 602.91M | 757.57M |
Cash Flow | |||||
| Free Cash Flow | -549.17M | -675.00M | -755.94M | -506.06M | -483.57M |
| Operating Cash Flow | -549.17M | -674.88M | -755.65M | -502.73M | -481.17M |
| Investing Cash Flow | 0.00 | -116.00K | -284.00K | 229.31M | -2.40M |
| Financing Cash Flow | 847.96M | 346.81M | -7.54M | 1.12B | -4.86M |
Hansa Biopharma AB Technical Analysis
Hansa Biopharma AB Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | kr2.07B | 9.60 | 167.77% | ― | 2687.51% | ― | |
56 Neutral | kr3.14B | -5.27 | ― | ― | -5.69% | 21.58% | |
55 Neutral | kr1.07B | 7.07 | 81.19% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | kr1.42B | -5.81 | -36.52% | ― | 533.73% | 20.92% | |
44 Neutral | kr2.87B | -5.68 | -71.87% | ― | -91.85% | -6.65% | |
44 Neutral | kr1.01B | -7.05 | -35.03% | ― | ― | 25.14% |
Hansa Biopharma AB Corporate Events
Hansa Biopharma has had its Biologics License Application for imlifidase accepted for review by the U.S. Food and Drug Administration, a key regulatory milestone for its first-in-class IgG-cleaving enzyme therapy. The filing is backed by pivotal Phase 3 ConfIdeS data showing significantly improved kidney function and dialysis independence in highly sensitized kidney transplant patients, potentially strengthening Hansa’s position in transplant medicine and expanding treatment options for those who struggle to receive compatible organs.
Imlifidase, already conditionally approved as IDEFIRIX in several European markets as well as in Australia and Switzerland, is designed to rapidly inactivate donor-specific antibodies to enable HLA-incompatible kidney transplantation. The FDA’s acceptance of the application, supported by a generally well-tolerated safety profile and long-term follow-up commitments, underscores regulatory momentum that could translate into broader global adoption and greater access for end-stage renal disease patients facing long wait times for transplantation.
The most recent analyst rating on (SE:HNSA) stock is a Hold with a SEK40.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.
Hansa Biopharma reported a strong fourth quarter, with revenue rising 135% year-on-year to 76.0 MSEK and full-year revenue reaching 222.3 MSEK, driven by 46% growth in IDEFIRIX product sales and broader uptake across key European markets, including Germany and progress on temporary funding in Catalunya, Spain. The company strengthened its balance sheet via a directed share issue of about 671.5 MSEK, reorganized its European and international commercial and medical affairs leadership, and ended the year with 701.1 MSEK in cash and short-term investments, while still posting a full-year loss of 529.3 MSEK as it invests in pipeline expansion.
Strategically, Hansa submitted a Biologics License Application to the U.S. FDA for imlifidase in desensitization of highly sensitized kidney transplant candidates, with a potential priority review decision that could set a PDUFA date as early as August 2026 and a European confirmatory PAES trial readout expected mid-2026. The clinical portfolio advanced with initial data from the GNT-018-IDES gene therapy pre-treatment trial in Crigler–Najjar syndrome demonstrating rapid AAV antibody removal, a decision to progress HNSA-5487 into Guillain-Barré syndrome following planned FDA discussions, and a setback in the anti-GBM Phase 3 study where the primary endpoint was not met due to unexpectedly strong outcomes from optimized standard of care, underscoring both the promise and risk in Hansa’s rare disease pipeline for investors and patients.
The most recent analyst rating on (SE:HNSA) stock is a Hold with a SEK36.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.
Hansa Biopharma will publish its year-end report for January–December 2025 on 11 February 2026 and hold a conference call the same day, during which senior management will review financial results and provide an update on the company’s business and development pipeline. The webcasted presentation, supported by slides available on the company’s website, underscores Hansa’s efforts to maintain transparency with investors and other stakeholders as it advances its IgG-cleaving enzyme platform and late-stage assets in rare immunological diseases.
The most recent analyst rating on (SE:HNSA) stock is a Hold with a SEK37.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.
Hansa Biopharma has been awarded the 2025 SwedenBIO Award, recognizing the company’s role in converting Swedish scientific excellence into global medical impact through its pioneering enzyme technology that enables life-saving transplantation for highly sensitized patients. The accolade underscores Hansa’s growing international profile and momentum going into 2026, as it advances strong U.S. Phase 3 data, prepares for an FDA review, and anticipates a key Phase 3 readout from its European trial later this year—developments that could further strengthen both the company’s commercial position and Sweden’s standing as a leader in life science innovation.
The most recent analyst rating on (SE:HNSA) stock is a Hold with a SEK36.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.
Hansa Biopharma has submitted a Biologics License Application to the U.S. Food and Drug Administration for imlifidase as a desensitization treatment for highly sensitized adult patients undergoing deceased donor kidney transplantation, and has requested priority review following Fast Track and Orphan Drug designations. The application is backed by the pivotal U.S. Phase 3 ConfIdeS trial, which showed significantly improved kidney function and dialysis independence at 12 months versus control, reinforcing imlifidase’s potential to reshape access to transplantation for this hard‑to‑treat population and to expand Hansa’s presence in the U.S. renal transplant market if approval is granted.
The most recent analyst rating on (SE:HNSA) stock is a Buy with a SEK111.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.
Hansa Biopharma AB announced that CEO Renée Aguiar-Lucander will present at J.P. Morgan’s 44th Annual Healthcare Conference in San Francisco on 14 January 2026, joined by key members of the executive team including the CFO, COO, CMO and CLO. Participation in this high-profile investment conference, alongside one-on-one meeting opportunities arranged through a neighboring corporate access event, underscores Hansa’s efforts to raise its visibility among global healthcare investors and industry leaders as it advances its pipeline of treatments for rare immunological diseases.
The most recent analyst rating on (SE:HNSA) stock is a Buy with a SEK111.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.
Hansa Biopharma announced that its Phase 3 trial for the treatment of anti-glomerular basement membrane (anti-GBM) disease with imlifidase did not meet its primary endpoint of improving renal function. Despite this, the trial showed that 60% of patients treated with imlifidase and standard care did not require dialysis at six months, a significant improvement over historical outcomes. The trial’s results highlight the potential benefits of aggressive treatment for anti-GBM patients, though the imlifidase treatment did not achieve statistically significant results. The company remains optimistic about imlifidase’s potential in other areas, such as gene therapy and kidney transplantation.
The most recent analyst rating on (SE:HNSA) stock is a Hold with a SEK31.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.
Hansa Biopharma AB announced a reorganization of its European and International Commercial and Medical Affairs operations to enhance performance and predictability in 2026. The changes include appointing Max Sakajja as Vice President, General Manager Europe and International, and implementing operational adjustments to improve accountability and collaboration. These strategic moves aim to support the company’s growth in Europe and the UK, improve transparency and forecasting, and position Hansa Biopharma for sustainable revenue growth.
The most recent analyst rating on (SE:HNSA) stock is a Hold with a SEK31.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.